ENOV vs USPH
ENOV: A medical technology company providing a comprehensive continuum of orthopedic care, from injury prevention and rehabilitation products to surgical reconstructive implants. USPH: A roll-up platform consolidating fragmented outpatient physical therapy and occupational therapy clinics while building a B2B workplace injury prevention and ergonomics business serving Fortune 500 employers.
Side-by-side fundamentals
| Metric | ENOV | USPH | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $26.55 | $74.38 | |
| Market cap as of 2026-07-23 | $1.5B | $1.1B | |
| P/E as of 2026-07-23 | n/a | 32.79 | |
| PEG as of 2026-07-23 | -0.04 | 8.89 | ENOV lower |
| Net margin as of 2026-07-23 | -49.9% | +4.4% | USPH higher |
| Gross margin as of 2026-07-23 | +60.4% | +19.0% | ENOV higher |
| Operating margin as of 2026-07-23 | -47.1% | +10.0% | USPH higher |
| ROE as of 2026-07-23 | -60.1% | +7.1% | USPH higher |
| ROA as of 2026-07-23 | -26.6% | +2.9% | USPH higher |
| Debt / equity as of 2026-07-23 | 0.90 | 0.44 | USPH lower |
| Revenue growth (YoY) as of 2026-07-23 | +6.0% | +13.7% | USPH higher |
| Revenue CAGR (3y) SEC XBRL | +12.9% | +12.2% | ENOV higher |
| Dividend yield as of 2026-07-23 | n/a | +2.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 1.47 | 1.13 | |
| 1-year return as of 2026-07-22 close | +3.0% | -0.9% | ENOV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.